Caprock Group LLC Buys 1,096 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Caprock Group LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 39,184 shares of the pharmaceutical company’s stock after purchasing an additional 1,096 shares during the quarter. Caprock Group LLC’s holdings in Vertex Pharmaceuticals were worth $15,780,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also added to or reduced their stakes in VRTX. Northwestern Mutual Wealth Management Co. boosted its stake in Vertex Pharmaceuticals by 92.2% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 15,942 shares of the pharmaceutical company’s stock worth $7,471,000 after purchasing an additional 7,647 shares during the period. Cetera Investment Advisers increased its stake in Vertex Pharmaceuticals by 2.3% in the 2nd quarter. Cetera Investment Advisers now owns 52,013 shares of the pharmaceutical company’s stock worth $24,379,000 after purchasing an additional 1,146 shares during the period. Sanctuary Advisors LLC purchased a new position in Vertex Pharmaceuticals in the 2nd quarter worth approximately $13,768,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $11,104,000. Finally, Centaurus Financial Inc. increased its stake in shares of Vertex Pharmaceuticals by 9.5% during the second quarter. Centaurus Financial Inc. now owns 1,569 shares of the pharmaceutical company’s stock valued at $735,000 after buying an additional 136 shares during the period. Institutional investors own 90.96% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. HC Wainwright boosted their target price on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the company a “buy” rating in a research note on Friday. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday. UBS Group boosted their target price on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the company a “buy” rating in a research note on Tuesday, November 5th. Canaccord Genuity Group lifted their price target on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a “sell” rating in a research report on Wednesday, November 6th. Finally, Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $495.36.

Vertex Pharmaceuticals Trading Up 3.8 %

Shares of Vertex Pharmaceuticals stock opened at $454.94 on Friday. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $377.85 and a fifty-two week high of $519.88. The stock has a 50 day moving average of $434.34 and a 200 day moving average of $463.31. The firm has a market capitalization of $117.16 billion, a price-to-earnings ratio of -227.74, a PEG ratio of 2.29 and a beta of 0.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same period last year, the business posted $3.67 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. As a group, research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.